The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
ERK1/2 and p38α/β Signaling in Tumor Cell Quiescence: Opportunities to Control Dormant Residual Disease
Open accessAbstract
Systemic minimal residual disease after primary tumor treatment can remain asymptomatic for decades. This is thought to be due to the presence of dormant disseminated tumor cells (DTC) or micrometastases in different organs. DTCs lodged in brain, lungs, livers, and/or bone are a major clinical problem because they are the founders of metastasis, which ultimately kill cancer patients. The problem is further aggravated by our lack of understanding of DTC biology. In consequence, there are almost no rational therapies to prevent dormant DTCs from surviving and expanding. Several cancers, including melanoma as well as breast, prostate, and colorectal carcinomas, undergo dormant periods before metastatic recurrences develop. Here we review our experience in studying the cross-talk between ERK1/2 and p38α/β signaling in models of early cancer progression, dissemination, and DTC dormancy. We also provide some potential translational and clinical applications of these findings and describe how some currently used therapies might be useful to control dormant disease. Finally, we draw caution on the use of p38 inhibitors currently in clinical trials for different diseases as these may accelerate metastasis development. Clin Cancer Res; 17(18); 5850–7. ©2011 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Microenvironmental regulation of metastasis
Joyce, J. A., & Pollard, J. W. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2618 · Cited by 3,684
Reversal of human cellular senescence: roles of the p53 and p16 pathways
Beauséjour, C. M., Krtolica, A., Galimi, F., Narita, M., Lowe, S. W., Yaswen, P., & Campisi, J. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg417 · Cited by 1,457
Phosphatase‐mediated crosstalk between MAPK signaling pathways in the regulation of cell survival
Junttila, M. R., Li, S., & Westermarck, J. (2008) · The FASEB Journal · doi:10.1096/fj.06-7859rev · Cited by 826
Eyles, J., Puaux, A.-L., Wang, X., Toh, B., Prakash, C., Hong, M., Tan, T. G., Zheng, L., Ong, L. C., Jin, Y., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42002 · Cited by 506
Control of the Reversibility of Cellular Quiescence by the Transcriptional Repressor HES1
Sang, L., Coller, H. A., & Roberts, J. M. (2008) · Science · doi:10.1126/science.1155998 · Cited by 313 · cited 2×
“Dormancy of a tumor mass versus dormancy of tumor cells The lack of proliferation markers in surviving DTCs in patients and data from experimental systems suggest that DTC dormancy may be controlled by mechanisms of quiescence (5), a reversible growth arrest that can be brought about by different signals (29).”
BackgroundTranscriptional switch of dormant tumors to fast-growing angiogenic phenotype
Almog, N., Ma, L., Raychowdhury, R., Schwager, C., Erber, R., Short, S., Hlatky, L., Vajkoczy, P., Huber, P. E., Folkman, J., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2590 · Cited by 240
Cited by
Emerging Biological Principles of Metastasis
Lambert, A. W., Pattabiraman, D. R., & Weinberg, R. A. (2017) · Cell · doi:10.1016/j.cell.2016.11.037 · Cited by 3,067
Cancer stem cells as key drivers of tumour progression
Ayob, A. Z., & Ramasamy, T. S. (2018) · Journal of Biomedical Science · doi:10.1186/s12929-018-0426-4 · Cited by 910
Tumor metastasis: moving new biological insights into the clinic
Wan, L., Pantel, K., & Kang, Y. (2013) · Nature Medicine · doi:10.1038/nm.3391 · Cited by 748
Metastatic Stem Cells: Sources, Niches, and Vital Pathways
Oskarsson, T., Batlle, E., & Massagué, J. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.02.002 · Cited by 708
EMT, CTCs and CSCs in tumor relapse and drug-resistance
Mitra, A., Mishra, L., & Li, S. (2015) · Oncotarget · doi:10.18632/oncotarget.4037 · Cited by 465
Metadata
- Authors
- Sosa, M. S., Avivar-Valderas, A., Bragado, P., Wen, H.-C., & Aguirre-Ghiso, J. A.
- Venue
- Clinical Cancer Research
- Published
- 2011-09-14
- Volume
- 17
- Issue
- 18
- Pages
- 5850-5857
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W1979964863
- Cited by
- 233
- References
- 6
- FWCI
- 5.79
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: ERK1/2 and p38α/β Signaling in Tumor Cell Quiescence: Opportunities to Control Dormant Residual Disease. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-10-2574
- The paper
- Sosa, M. S., Avivar-Valderas, A., Bragado, P., Wen, H.-C., & Aguirre-Ghiso, J. A. (2011). ERK1/2 and p38α/β Signaling in Tumor Cell Quiescence: Opportunities to Control Dormant Residual Disease. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-10-2574
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.